There is always one drugs trying to stake its place as being better than another. A new report suggests that tiotropium (Spiriva) may be “better” than a rival long-acting bronchodilator, salmetrol (Serevent), in a head-to-head comparison. What the “battle” was about was the length of time to having an exacerbation of COPD related symptoms (cough, sputum production, bronchitis, etc). The tiotropium brand had a longer time to exacerbation (187 days) than the salmetrol (145 days).
One word of caution, however, was the the trial was paid for by the manufacturer of Spiriva and there were several paid investigators by the same company. How this impacted the study is not clear but I always have a small degree of curiosity.
As always, let’s await further studies to confirm this report.